Faex Health Seeks Capital to Expand AI Smartphone Digestive Health Platform
New York, Thursday, 28 May 2026.
Faex Health is raising funds to scale its AI-powered smartphone stool analysis tool, aiming to grow U.S. health plan coverage and tackle global gastrointestinal diseases.
Expanding the Footprint in Employer and Payer Markets
On May 27, 2026, the Boulder, Colorado-based health technology startup Faex Health officially initiated a global fundraising round [1]. The capital injection is strategically designed to attract venture firms, strategic investors, and healthcare partners to scale the company’s proprietary gastrointestinal health platform [1]. While Faex Health remains a privately held entity without a public ticker symbol [alert! ‘No ticker symbol is provided in the source material as the company is a private startup’], this financial move aims to rapidly accelerate its go-to-market operations across United States health plans and employer-sponsored benefits programs [1].
Clinical Validation and Global Public Health
Leading up to the late-May 2026 fundraising announcement, Faex Health secured several critical operational milestones that validate its clinical and commercial viability [1]. In the commercial sector, the startup successfully onboarded its first enterprise-level customer, an organization that provides benefits to a workforce of over 50,000 employees [1]. Simultaneously, the company has pushed aggressively into international clinical validation [1]. On May 18, 2026, Faex Health established a partnership with Hospital Dr. Sótero del Río in Chile [1]. This collaboration centers on a clinical trial designed to detect colorectal abnormalities using the company’s smartphone-based diagnostic tools [1].
Bridging the Gap in Gastrointestinal Care
The strategic direction is heavily influenced by the leadership’s view on the current state of preventative care [1]. Landon Nattrass, co-founder and Chief Executive Officer of Faex Health, noted that digestive health is often neglected in standard healthcare monitoring, despite its well-documented links to severe systemic diseases [1]. According to Nattrass, the incoming capital will be instrumental in strengthening the company’s clinical validation efforts and expanding the accessibility of its scalable gastrointestinal tools across both public-health environments and commercial markets [1].